T H E past two decades have witnessed considerable advances on many dermatological fronts. The tendency to regard the skin as an isolated organ is being replaced by considering the relationship between the skin and the other organs and the organisms as a whole. As more workers in the basic sciences focus their attention on the normal and diseased skin emphasis has been shifted from clinical descriptive dermatology to broader concepts of disease processes and disordered function of bodily systems, thus bringing dermatology into line with the thinking and practice of general medicine.
Speaking broadly, advances may be grouped into 3 main headings and result from: (l) improved therapeutics; (2) application of basic research techniques; and (3) interrelationships between skin diseases and those of other organs or systems.
As it is not possible in the space allocated to cover all the advances which have been made in recent years only those of major importance and widest general interest will be discussed.
Therapeutics
Dermatology shared with all other branches of medicine the benefits brought about by the introduction of the parenterally administered synthetic adrenal corticosteroid group of therapeutic agents as suppressors of inflammatory processes. This advance must however be kept in perspective as it was soon apparent that the price to be paid in terms of side effects was in many instances too high to justify the use of these preparations in chronic non-fatal dermatological conditions. While it is known that systemic administration of corticosteroids will suppress the manifestations of many chronic skin diseases experience with them has resulted in most dermatologists restricting their use to two clearly defined categories of cutaneous disease. Long term use may be indicated in otherwise fatal conditions such as the pem-phigus group of blistering diseases and in acute disseminated lupus erythematosus. In these conditions high doses may be necessary initially, in the order of 80 to 100 mg. prednisolone daily, reducing as rapidly as the clinical manifestations will allow to the smallest maintenance dose which will keep the patient symptom free. This is usually in the region of 10 to 20 mg. prednisolone daily although in some instances it may be even lower. The other group which involves short term systemic corticosteroid therapy is composed of acute, widespread, self-limiting conditions such as severe drug reactions, severe erythema multiforme with mucosal involvement and widespread contact dermatitis. In these initial dosage is moderate-40 to 50 mg. prednisolone daily reducing by 5 to 10 mg. daily, the entire course of therapy occupying 7 to 10 days. Used in this way suffering is greatly reduced and in most instances the course of the disorder shortened, allowing a quicker return to work. Systemic corticosteroid therapy is in general contraindicated in such chronic benign conditions as widespread atopic dermatitis and psoriasis. Such conditions tend to require progressively higher dosage to control the skin lesions. This leads to the development of one or other of the generalised side effects of such therapy, necessitating its withdrawal and resulting in a rebound of the skin condition. Such rebounds are of unprecedented ferocity and extremely slow to respond to more conventional therapy.
The introduction of topical hydrocortisone in 1950 must be regarded as one of the most important events in the local therapy of inflammatory skin disease. As new and more potent compounds were synthesised for systemic use many of these were, in suitable vehicles, adapted for topical use. H soon became apparent, however, that systemic potency could not be directly related to surface potency as shown by the fact that compound betamethasone was assessed as 20 to 30 times more potent than hydrocortisone when administered by mouth (Coke, 1961; Glyn & Fox, 1961) but only 10 times more potent than hydrocortisone when applied topically (Vickers, 1962) . The turning point in the more logical development of topical corticosteroids came when McKenzie and Stoughton (1962) and McKenzie (1962) reported that when corticosteroids dissolved in alcohol were applied to the human skin they produced areas of vasoconstriction. Compounds which exhibited most powerful vasoconstriction were found to be most efficaceous in clinical practice. While subsequent experience has shown that this vasoconstriction test is of low precision, it remains today the most useful method of screening large numbers of potential topical corticosteroids.
Today there are a number of extremely potent topical corticosteroids-betamethasone 17-valerate, fluocinolone acetonide, triamcinolone acetonide, flurandrenolone, flumethasone pivalate, beclomethasone dipropionate and fluocortolone. All of these compounds are extremely effective in rapidly suppressing the manifestations of the dermatitis reaction at any of its phases. Results with psoriasis and other chronic inflammatory skin conditions are much more variable. The introduction in 1961, by Sulzberger and Witten, of occlusive dressing by means of thin plastic sheeting greatly increased the therapeutic efficiency of the already potent topical corticosteroids. The results obtained in such chronic skin diseases as extensive psoriasis were extremely dramatic. Following the application of a thin coating of fluocinol-II Z5 21 15 I' 1 I I 4 5 74 one acetonide or betamethasone valerate ointment the affected areas are covered by polythene sheeting and left undisturbed for 24 hours. After 4 or 5 days of this regime even the most resistant psoriasis yielded and the skin appeared clinically normal. Patients with widespread disease were naturally delighted at the rapid disappearance of their lesions and the fact that the treatment was so clean compared to the conventional therapy with crude coal tar. It was not long, however, before disturbing reports appeared in the literature concerning the systemic effects of this kind of therapy where large areas of the body surface were occluded. Scoggins (1962) first reported a decreased output in urinary ketosteroids and this observation was confirmed and extended by Kirketerp (1964) . Gill and Baxter (1964) recorded a sharp drop in plasma cortisol levels in patients with extensive psoriasis treated with ointments containing fluocinolone acetonide, flurandrenalone acetonide and triamcinolone acetonide under occlusive dressings. Numerous workers have confirmed the adrenal suppressive effect of corticosteroids under occlusive dressings and some have noted temporary depression of pituitary function. Figure 1 shows typical findings with regard to plasma cortisol and urinary 17 steroids in a patient treated with one of the potent corticosteroids under polythene occlusion. It should be emphasised that on cessation of treatment the plasma cortisol urinary steroids and impaired pituitary function rapidly return to normal and no reports have appeared in the literature of adrenal failure during such therapy. .n.
extensive application of topical steroids should be avoided in children.
In addition to these studies indicating adrenal suppression clinical experience showed that using occlusive therapy for chronic skin disease was followed by a rapid and often severe recrudescence of the disease as soon as the therapy was stopped. Other side effects have been reported following prolonged or excessive use of corticosteroid preparations, pyogenic folliculitis being a particularly troublesome one. Ives and commented on the marked increase in fungus infections, especially in the flexural areas, and Shuster et al. (1967) recorded the appearance of striae and cutaneous atrophy. More recently Sneddon (1969) has drawn attention to the flushing and telangiectasia produced on facial skin by the fluorinated corticosteroids. This is particularly noticeable in patients with rosacea who have been treated with these preparations. Withdrawal is followed by an acute exacerbation of the disease with severe pustulation.
Another danger associated with topical corticosteroid therapy stems from the manufacturers' inclusion of one or more antibiotics in these preparations. Neomycin and framycetin are particularly potent cutaneous sensitisers (Kirkton & Munro-Ashman, 1965) . The incorporation of a corticosteroid masks the onset of this sensitivity which may be unrecognised for a considerable time. Once established neomycin sensitivity persists as a chronic dermatitis which proves extremely recalcitrant to treatment. It is thus very easy to convert a relatively trivial selflimiting contact dermatitis into a chronic dermatitis. The use of such combined steroid antibiotic preparations is to be deprecated. Should secondary infection be present it should be treated first by the appropriate antibiotic followed, if necessary, by the steroid preparation. In flexural and intertriginous areas the risk of superadded infection may however be reduced by using the steroid preparation in combination with an antibacterial such as the organic iodine compound chlor-iodohydroxyquinolone. It is thus obvious that the benefits of topical corticosteroid preparations are not obtained Recent Advances in Dermatology without cost to the patient. There is no doubt however of the enormous benefits which have accrued from the proper use of these compounds. Applied for limited periods to acute irritant and contact dermatitis they greatly reduce discomfort, allowing a rapid return of the skin to normal and the patient to resume his work. The use of the more potent ones in chronic disorders such as psoriasis and atopic dermatitis must be approached with caution. Apart from the side effects of infection, adsorption and cutaneous atrophy there is a tendency with prolonged use for them to lose their efficacy.
Patients with chronic skin disease should be discouraged from their use and encouraged to control their disease with older, empirical, but none the less useful remedies. Their use in chronic skin disease is mainly in the rapid control of acute exacerbations when they can be used in conjunction with standard treatment. One very real danger of their use in chronic conditions is that some patients become addicted to their use (Shuster & Williams, 1961) .
The future developments in topical corticosteroid therapy must centre around the development of compounds devoid of fibroblast-destroying activity and of low systemic absorption. The work of Fountain and his colleagues (1969) showing that the rate of release of corticosteroids can be influenced by varying the constituents of the base should help in the development of a more logical and controlled approach to the problems of topical corticosteroid therapy.
The management of acne vulgaris is one of the major therapeutic problems in the teenager and young adult. The attitude that it is an expression of 'growing up' cannot be deprecated too strongly because no one can foretell when the mildest case will suddenly deteriorate with the extensive pustule and cyst formation and subsequent scarring. While the mainstay of acne therapy is still peeling of the surface keratin either by oldfashioned sulphur paste or erythema doses of ultra violet light, the introduction of oral tetracyclines by Andrews et al. (1951) marked a significant advance in the treatment of this disease. Cronk and his colleagues (1956) treated 72 cases with oral tetracycline alone, commencing with 250 mg. four times daily and reducing to 250 mg. once or twice daily, continuing treatment for 1 to 9 months. These authors found a 50 per cent reduction in lesions at 30 days and a 62 per cent at 60 days. These findings were confirmed by other workers, Stritzler and Frank (1960) , Wansker (1961) , Stewart et al. (1963) and Cornbleet (1964) . Despite two reports to the contrary (Smith et al., 1962; Crounse, 1965) most dermatologists are agreed that oral tetracycline is of considerable value in the treatment of resistant and severe acne. The average dose is 250 mg. twice daily, continued for a period of 3 months followed by a rest period of 1 month, the course being repeated as necessary. At this dosage none of the theoretical side effects, such as superinfection with antibiotic-resistant organisms such as Proteus or Candida have been reported. Tetracyclines, of course, should not be given in the presence of hepatic disease or during pregnancy. Oral tetracycline 250 mg. once or twice daily is also the most effective treatment for acne rosacea (Sneddon, 1966) .
The beneficial effects of tetracyclines in acne vulgaris are not apparently due to its antibiotic effect in the generally accepted sense as pyogenic organisms play little part in the pathogenesis of acne (Shehadeh & Kligman, 1963) . It has been established that freshly-formed sebum contains little if any free fatty acids (Nicolaides & Wells, 1957) and that these are formed mainly by the action of bacterial lipases. A diphtheroid organism, Corynebacterium acnes, is a commensual in the pilosebaceous follicle and it would appear that this organism, which is exquisitely sensitive to tetracycline, is the main source of these lipases. When free fatty acids gain access to the tissues an intense inflammatory reaction is induced (Strauss & Kligman, 1960) . Frankel and his colleagues (1965) found that in a group of acne patients taking 1 g. of tetracycline daily the concentration of total fatty acids and the rate of sebum production remained unaltered but the concentration of free fatty acid was considerably reduced. Clinical improvement occurred coincidentally with the decline in free fatty acids. 76 While it is difficult to estimate the precise incidence of psoriasis it is generally agreed that about 2 per cent of the population in this country suffer from the disease. Local therapy, while effective if conscientiously carried out, is dirty, time-consuming and anti-social. Corticosteroid therapy, either systemically or topically, is unsatisfactory and potentially dangerous from side effects. Because extensive psoriasis has a profound effect on a sufferer's career prospects and social activities, it is not surprising that alternative forms of therapy have been investigated. While the use of folic acid antagonists for the treatment of psoriasis was first suggested by Gubner et al. (1951) it was the work of Rees and his colleagues (1964) which established the effectiveness and relative safety of methotrexate or aminopterin in severe resistant psoriasis. These authors stressed the need for careful selection of cases on the basis of 'life ruining psoriasis', and emphasised the need for the patient to be in good general health with particular reference to hepatic and renal function. In the first series to be reported by British authors, Ryan and his colleagues (1964) concluded that folic acid antagonists were consistently effective in producing some improvement in psoriasis, albeit temporary. While the treatment was not free from side effects, these, if the drug were stopped immediately, were rapidly reversible, this being a considerable advantage over systemic corticosteroid treatment. Since these reports there has been considerable debate as to the efficacy and dangers of this type of therapy. Auerbach (1964) found parenteral methotrexate to be successful in patients who had failed to respond to either aminopterin or methotrexate administered by mouth. Ryan et al. (1965) reported evidence of chromosomal damage in patients treated with methotrexate although other workers have failed to confirm this finding. Coe and Bull (1968) recorded three instances, one fatal, of hepatic cirrhosis of insidious onset in patients receiving long term antifolate therapy for psoriasis. These authors suggest that the methotrexate accumulates in the liver, eventually saturating dihydrofolate reductase reserves, thus interfering with tetrahydrofolate acid formation and nucleic acid synthesis, resulting in cellular dysfunction and leading to liver cell necrosis with subsequent cirrhosis.
It is justifiable to question the validity of using such a potentially dangerous form of therapy in a non-lethal disease such as psoriasis. There is however the occasional case in which the disease is so resistant to other forms of therapy that a calculated risk may be justified. Such patients must be very carefully selected and adequately monitored, with particular attention to hepatic function.
Commenting on the paper of Coe and Bull, Auerbach (1969) states that 'when a significant amount of clearing is achieved conventional therapy should be used: the methotrexate should be reserved only for those times when the patient's psoriasis is threatening to flare to the point of disability. The concept of a maintenance dose has no place in methotrexate therapy'. This statement sums up the proper approach to methotrexate therapy if such treatment is deemed advisable.
Applications of basic research techniques
The therapeutic advance in the management of acne vulgaris has already been discussed. Further advances in the treatment of this exceedingly common and potentially disfiguring skin disease can only result by elucidation of its aetiology. It has long been known that acne vulgaris commences at puberty (with the exception of cases occuring in young children with adrenal cortical tumours), that it never occurs in eunuchs and that it is made worse by the administration of androgens. Utilising the techniques of histochemistry, Baillie et al. (1965) reported that in areas of human skin prone to develop acne vulgaris the sebaceous glands were able to utilise a number of hydroxysteroid compounds by virtue of their complement of NAD-dependant hydroxysteroid dehydrogenases. This was the first indication that the sebaceous glands themselves might be involved in steroid metabolism. These histochemical techniques were modified and improved by Muir and her colleagues (Muir et al.• 1968a) to allow of semiquantitation Recent Advances in Dermatology and standardisation with regard to optimum conditions and concentrations of substrate (Muir et al., 1968b) . In view of the fact that it is known that sebaceous activity is maintained in part in castrates by adrenal steroids (Pochi et al., 1962 (Pochi et al., , 1963 and that the 3 f3-hydroxysteroid dehydrogenases are concerned with more general steroid synthesis, attention has been focused on the activity of the 3 f3-hydroxysteroid dehydrogenases using the adrenal steroid dehydroepiandrosterone (DHA), the known precursor of androgens, as substrate. Useful as these studies have been, they have been limited by the inability to isolate and chemically characterise the end product, a major disadvantage to most histochemical procedures. To overcome these difficulties Cameron et al. (1966) incubated thin slices of human skin along with [7a-3 H] dehydroepiandrosterone and obtained small amounts of [3H] testosterone. Choosing areas which contained the same number of sebaceous glands per unit area they found that shoulder skin (acne area) produced more [3H] testosterone than thigh skin (non-acne area). In more elaborate experiments, utilising the improvements (1968b), introduced by Muir and her colleagues Chakraborty et al. (1970) repeated the incubations of human skin with [7a-3 H] dehydroepiandrosterone. Their results, which will be reported in detail elsewhere, are of interest in that they did not identify any testosterone following completion of the incubations. The main metabolite recovered was androstenedione, a precursor of testosterone. The failure to isolate testosterone may be due to a lack of reduced co-factors in the experimental system.
The amounts of androstenedione recovered were much greater from acne areas than from non-acne areas in young subjects but the difference was much less in subjects over 25 years of age. Other workers (Faredin et al., 1967a & b; Gallegos & Berliner, 1967) , utilising different incubation techniques, have also reported the formation of androstenedione from dehydroepiandrosterone by human skin. Androstenedione itself is about half as potent as methyl testosterone in stimulating human sebaceous activity (Strauss & Pochi, 1968) . It is thus clearly proven that human skin is capable of synthesising androgens from adrenal steroids. In view of the strict localisation of the 3,B-hydroxysteroid dehydrogenases to the sebaceous glands it would appear probable that these glands are the major source of production of androgens. Much further biochemical work is necessary however to identify all the metabolites and to confirm the increased production of these in areas of skin prone to acne vulgaris. Recently (Bruchovisky & Wilson, 1968) attention has been focused on Sa dihydrotestosterone as being the biologically active androgen and Northcutt et al. (1969) have shown that in the syndrome of the fat, hairless woman with testes the skin lacks the enzyme which reduces testosterone to Sa dihydrotestosterone, presumably thus accounting for the lack of hair. The production of excess androgens by the sebaceous glands in acne areas might well be responsible for the hyperkeratosis with the resultant blocking of the pilosebaceous duct which is known to be the first stage in the development of lesions of acne vulgaris. If this is the case the logical treatment of acne would be the development of antiandrogens which would block this process. Many chemical substances are known which exhibit antiandrogen effects in classical animal experiments. Before such substances can be effectively used in man, however, many problems have to be solved. There are so many substances available that some form of screening is necessary. Recently Archbold and have used the total lipid content of rat skin for this, and Caiman et al. (1969) have shown the potential of semi-quantitative histochemical techniques utilising human sebaceous glands. Perhaps the major problem however arises once a suitable antiandrogen is discovered, namely to confine its activity to the sebaceous glands without interfering with the steroid metabolism of other organs. No doubt these problems will be overcome eventually and lead to a really effective treatment for acne vulgaris.
Dermatology has reaped considerable benefits from the rapid growth of the science of immunology. Some of these, such as the immunofluorescent studies of Beck (1961) and Rowell and Beck (1967) advancing our 78 knowledge of the connective tissue disorders, are generally well known. It has long been known that the variety of infantile dermatitis known as atopic dermatitis is intimately connected with an inherited familial syndrome of allergy associated with reaginic antibodies which, in addition to the inflammation of the skin, includes allergic asthma and hay fever. One of the problems in the management of such children is to determine the role of allergens in the production of the dermatitis. Routine skin testing of such children is now little used because of difficulties in interpretation of the many positive tests usually obtained. Ishizaka et al. (1966) made a detailed study of sera from atopic individuals and concluded that reaginic activity was associatied with a subfraction of the IgA immunoglobulins which they designated IgE. This IgE had physicochemical properties similar to an immunoglobulin which Johansson and Bennich (1967) isolated from the serum of a patient suffering from myelomatosis to which they gave the designation IgND. Stanworth et al. (1967) showed that IgND inhibited the Prausnitz-Kiiestner reaction, thus indicating the probable identity of IgE and IgND. Johansson (1967) reported raised levels of IgND in 63 per cent of patients suffering from allergic asthma and in this communication refers to unpublished data of his own and his colleague Bennich on elevated IgND levels in atopic dermatitis. Apart from elucidating the essential nature of reagins these observations offer potential improvements in the diagnosis and management of the atopic state. Wide et al. (1967) developed a method of measuring immunoglobulins of the IgND class in serum. The test, the radioallergosorbent test (RAST) was applied in the investigation of a series of atopic individuals utilising fourteen antigens which are commonly implicated in the atopic state. There was a 96 per cent agreement between the results thus obtained and an antigen provocation test. Although the RAST is a complicated and sophisticated procedure its use as an investigative tool should result in a positive identification of the antigens of real significance in either the initiation of or the exacerbations of atopic dermatitis and possibly chronic urticaria.
Immunologists have also contributed significantly to the understanding of the process of naturally occurring blisters in the skin and have provided a most useful diagnostic test in the differential diagnosis of blistering disease of the skin. In 1964 Beutner and Jordan reported the finding of a circulating antibody to an intercellular antigen in squamous epithelium in patients suffering from the serious and often fatal blistering skin disease, pemphigus vulgaris. This antibody was demonstrated by the technique of indirect immunofluorescent staining and was not found in normal control sera or in sera from other blistering diseases. Other workers (Waldorf et al., 1966) have confirmed the presence of this intercellular antibody and it has been found regularly in the other variants of pemphigus vulgaris, namely pemphigus vegetans, pemphigus foliaceus and pemphigus erythematosus (Senear-Usher syndrome) (Beutner et al., 1965; Beutner et al., 1968) .
The essential histological lesion in all forms of pemphigus is the formation of an intraepidermal blister subsequent to loss of cohesion between neighbouring epidermal cells (acantholysis) caused by damage at their intercellular points of contact (desmosomes) . It is at the desmosomes that the immunofluorescent staining is seen and it would appear that the pathological process is a direct result of a cytotoxic effect of the circulating antibody. The antibody itself has been identified as a globulin associated with the IgG complex and the fact that it binds with complement in the blistered and surrounding clinically normal skin suggests an in vivo reaction (Cormane & Chorzelski, 1957) .
A number of points of considerable practical importance stem from these observations. Firstly it is possible to separate quickly and accurately cases of pemphigus from other blistering diseases, thus allowing therapy to be started with the minimum delay. This all the more so when it is realised that about half of the cases of pemphigus present with lesions on either the buccal or genital mucous membranes for up to two years before the skin lesions appear. All cases of persistent and unexplained mouth or vulvar 'ulceration' Recent Advances in Oermatology sho uld thus be screened for the presence of pemphigus antibodies. Secondly, as it has been shown (Chorzelski et al., 1966) that the titre of the circulating antibody is proportional to the clinical severity and falls with remissions either therapeutically induced or occurring naturally, it can be used as a means of assessing and monitoring therapy.
The skin in relation to general medicine A natural consequence of the realisation that the skin is not an isolated organ has led a number of investigators to turn their attention to the effects of skin disease in other organs and to the possible effects of disorders of other organs on the skin. Shuster (1963) reported a group of patients with widespread erythrodermia due to either extensive psoriasis or chronic dermatitis who exhibited raised jugular venous pressure, hepato-splenomegaly, tachycardia, increased pulse pressure and dependant oedema associated with warm extremities. These signs, of high output cardiac failure, spontaneously regressed as the skin condition cleared. Fox and his colleagues (1965) in a more detailed study of erythrodermic patients concluded that there was an increase of up to two-thirds in skin blood flow as compared with normal subjects fully vasodilated by heat. The four reports which have appeared in the literature measuring the cardiac output of patients with widespread erythrodermia are confusing and it is obvious that further study using the cardiological techniques now available is needed. Most patients with erythrodermia are in the older age group and it has long been known that mortality in this disorder is high (Abrahams et al., 1963) , and it may well be that this can be explained in part at least by high output cardiac failure caused by the increased cutaneous bloodflow.
Magnus and his colleagues (1961) extended our knowledge of disordered porphyrin metabolism when they described cases of cutaneous photosensitivity associated with a previously unrecognised type of erythropoietic porphyria for which they proposed the name erythropoietic protoporphyria. These authors noted that the levels of circulating protoporphyrins varied consider-7') ably in affected individuals but that the levels were directly related to the degree of photosensitivity. The clinical features tend to be relatively mild in the northern hemisphere, consisting of blistering in children and oedema or urticaria in adults, appearing on areas exposed to the sun. With the passage of time, thickening of the skin over the knuckles and fine linear radiating scars at the angles of the mouth are seen. In the southern hemisphere, particularly South Africa, the changes are severe with extensive scarring and premature ageing of the skin (Goldberg, 1966) . The diagnosis can be confirmed by estimation of the erythrocyte protoporphyrin level (normal 13.0-29.6fig.f100 ml. of erythrocytes: Rimington et al., 1963) of erythrocytes may be seen in iron deficiency anaemia. Before placing reliance on low values, therefore, iron deficiency states must be excluded.
In recent years it has become apparent that there is a definite association between certain chronic skin disorders and disease or dysfunction of the small intestine and that a number of different mechanisms are involved. Friedman and Hare (1965) reported four cases of chronic and widespread dermatitis associated with ma1adsorption whose skin cleared on withdrawing gluten from their diets, thus establishing a direct link between a skin disease and gluten enteropathy. Shuster and Marks (1965) investigated a group of patients with extensive chronic skin disease and found the majority to have an abnormally high faecal fat excretion on admission to hospital; this fell to normal when the skin was treated. It seems likely that the diversion of blood to the inflamed skin results in a relative ischaemia of the small intestine in spite of the increased cardiac output, giving rise to temporary steatorrhoea. No structural abnormalities in the gut were detected in three of these cases examined by intestinal biopsy. For this example of apparent 110 small intestinal dysfunction the authors suggested the name dermatopathic enteropathy. A considerable impetus to the study of intestinal structure and function in chronic skin disease was given by Watson et al. (1965) who in an investigation of sixty patients suffering from acne rosacea recorded twenty with abnormal jejunal mucosa as revealed with biopsy by a Crosby capsule. While their results have not been confirmed Marks et al. (1966) and Fraser et al. (1967) reported that approximately 70 per cent of cases of the chronic skin disease, dermatitis herpetiformis, had abnormalities in their jejunal mucosa varying from partial to complete villous atrophy. These findings have been confirmed and extended by a number of investigators (Fry et al., 1967; Marks et al., 1968) . Despite the high incidence of histological abnormalities in the jejunal mucosa only a small number of patients complain of gastrointestinal symptoms. Fry et al. (1967) and Fraser et al. (1969) noted low levels of serum IgM in a proportion of their patients with dermatitis herpetiformis of the same order as those which Hepner (1966, 1968) found in their patients with coeliac disease. There seems no doubt, then, that a large percentage of patients suffering from dermatitis herpetiformis have an associated enteropathy which in some instances is indistinguishable from coeliac disease.
It is difficult on the evidence available to explain this association although the incidence of 70 per cent appears too high to be fortuitous. The pathological processes in the skin and gut are totally dissimilar and it is therefore unlikely that the same aetiological agent is responsible for the skin and bowel lesions. In addition, while the skin lesions of dermatitis herpetiformis show an excellent therapeutic response to small doses of dapsone the bowel lesions are unresponsive to this therapy (Marks et al., 1966) . The total area of skin involved by dermatitis herpetiforrnis is relatively small, making it unlikely that the gut changes are one type of dermatopathic enteropathy. There is still some confusion in the literature concerning the effects on the skin lesions of a glutenfree diet. Fry et al. (1968) claimed that the skin lesions improved, or requried a lower dose of dapsone, when a gluten-free diet was given for a sufficient period of time. These findings are denied by Shuster et 01. (1968) and Marks and Shuster (1969) . From the available evidence it would appear that the skin lesions are independant of gluten sensitivity and as yet no logical explanation of this strong statistical relationship has been advanced. Until this has been clarified it is still necessary to treat the skin by dapsone and to withdraw gluten from the diet for the enteropathy.
